Linked Life Data

11861115

Source:http://linkedlifedata.com/resource/pubmed/id/11861115

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-2-25
pubmed:abstractText
A novel approach to treat hypertension is to interfere with the Renin-Angiotensin system (RAS) by blocking the binding of vasoconstrictive hormone Angiotensin II to the AT(1) receptor site. This approach led to the beneficial drug losartan (COZAAR) and other similar in structure to the antihypertensive drugs (sartans). In an effort to compare the stereoelectronic features of pharmacophoric segments of the different sartans, a research activity was initiated in our laboratory related to the conformational properties of these drugs. In a previous study, the structural features which determine the pharmacophoric segments of losartan were examined. In this study, the conformational properties of eprosartan (TEVETEN), a drug with fewer side effects, were examined. In addition, the superimposition ability of losartan and eprosartan with the peptide antagonist sarmesin was studied.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0731-7085
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-35
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist.
pubmed:affiliation
Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation. Vas. Constantinou 48, Athens, Greece.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't